JP5395432B2 - トリアゾール化合物ならびにこれを作製する方法および使用する方法 - Google Patents

トリアゾール化合物ならびにこれを作製する方法および使用する方法 Download PDF

Info

Publication number
JP5395432B2
JP5395432B2 JP2008528247A JP2008528247A JP5395432B2 JP 5395432 B2 JP5395432 B2 JP 5395432B2 JP 2008528247 A JP2008528247 A JP 2008528247A JP 2008528247 A JP2008528247 A JP 2008528247A JP 5395432 B2 JP5395432 B2 JP 5395432B2
Authority
JP
Japan
Prior art keywords
unsaturated
aromatic
alkyl
group
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008528247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506075A (ja
JP2009506075A5 (https=
Inventor
アショーク バッタチャルジー，
ゾルタン エフ． カンヨ，
エドワード シー． シェレール，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Rib X Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib X Pharmaceuticals Inc filed Critical Rib X Pharmaceuticals Inc
Publication of JP2009506075A publication Critical patent/JP2009506075A/ja
Publication of JP2009506075A5 publication Critical patent/JP2009506075A5/ja
Application granted granted Critical
Publication of JP5395432B2 publication Critical patent/JP5395432B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
JP2008528247A 2005-08-24 2006-08-24 トリアゾール化合物ならびにこれを作製する方法および使用する方法 Expired - Fee Related JP5395432B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71144305P 2005-08-24 2005-08-24
US60/711,443 2005-08-24
US76290706P 2006-01-26 2006-01-26
US60/762,907 2006-01-26
PCT/US2006/033645 WO2007025284A1 (en) 2005-08-24 2006-08-24 Triazole compounds and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013169594A Division JP5981401B2 (ja) 2005-08-24 2013-08-19 トリアゾール化合物ならびにこれを作製する方法および使用する方法

Publications (3)

Publication Number Publication Date
JP2009506075A JP2009506075A (ja) 2009-02-12
JP2009506075A5 JP2009506075A5 (https=) 2009-10-08
JP5395432B2 true JP5395432B2 (ja) 2014-01-22

Family

ID=37467427

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2008528247A Expired - Fee Related JP5395432B2 (ja) 2005-08-24 2006-08-24 トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP2008528168A Withdrawn JP2009506066A (ja) 2005-08-24 2006-08-24 トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP2013169594A Expired - Fee Related JP5981401B2 (ja) 2005-08-24 2013-08-19 トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP2015223733A Pending JP2016094421A (ja) 2005-08-24 2015-11-16 トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP2017141745A Pending JP2018008970A (ja) 2005-08-24 2017-07-21 トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP2018169395A Pending JP2019023194A (ja) 2005-08-24 2018-09-11 トリアゾール化合物ならびにこれを作製する方法および使用する方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2008528168A Withdrawn JP2009506066A (ja) 2005-08-24 2006-08-24 トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP2013169594A Expired - Fee Related JP5981401B2 (ja) 2005-08-24 2013-08-19 トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP2015223733A Pending JP2016094421A (ja) 2005-08-24 2015-11-16 トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP2017141745A Pending JP2018008970A (ja) 2005-08-24 2017-07-21 トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP2018169395A Pending JP2019023194A (ja) 2005-08-24 2018-09-11 トリアゾール化合物ならびにこれを作製する方法および使用する方法

Country Status (7)

Country Link
US (5) US8278281B2 (https=)
EP (3) EP3290427A1 (https=)
JP (6) JP5395432B2 (https=)
DK (1) DK1934238T3 (https=)
ES (1) ES2638427T3 (https=)
HR (1) HRP20171285T1 (https=)
WO (2) WO2007025284A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5383037B2 (ja) 2004-02-27 2014-01-08 リブ−エックス ファーマシューティカルズ，インコーポレイテッド 大環状化合物およびそれらを製造し使用する方法
JP2009506063A (ja) 2005-08-24 2009-02-12 リブ−エックス ファーマシューティカルズ，インコーポレイテッド トリアゾール化合物ならびにこれを作製する方法および使用する方法
EP3290427A1 (en) * 2005-08-24 2018-03-07 Melinta Therapeutics, Inc. Triazole compounds and methods of making and using the same
WO2008106224A1 (en) * 2007-02-28 2008-09-04 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
EP2176216B1 (en) * 2007-07-06 2012-04-25 Paratek Pharmaceuticals, Inc. Methods for synthesizing 9-substituted minocycline
JP2011026260A (ja) * 2009-07-28 2011-02-10 Central Glass Co Ltd ３位に脱離基を有する２−フルオロプロピルアミン保護体または該アミンｎ−アルキル保護体
CN101619085B (zh) * 2009-08-11 2015-04-22 沈阳药科大学 红霉素衍生物及其作为肿瘤细胞增殖抑制剂的用途
AR092278A1 (es) * 2012-08-31 2015-04-08 Novartis Ag Proceso de obtencion de derivados n-acilicos de bifenil-alanina e intermediarios relacionados
HK1244211A1 (zh) 2014-11-14 2018-08-03 Melinta Therapeutics, Inc. 治疗、预防或降低皮肤感染风险的方法
WO2018191682A1 (en) * 2017-04-15 2018-10-18 Melinta Therapeutics, Inc. Triazole compounds and methods of making and using the same
CN110108826A (zh) * 2019-05-24 2019-08-09 内蒙古蒙牛乳业（集团）股份有限公司 乳或乳制品中氟苯尼考胺的检测方法
US20210371389A1 (en) * 2020-04-24 2021-12-02 Kansas Soybean Commission One-step synthesis of soybean polyols
WO2022146980A1 (en) 2020-12-28 2022-07-07 Georgia Tech Research Corporation Compositions and methods for inhibiting fibrosis, inflammation and cancer
CN115745823B (zh) * 2022-11-03 2024-02-23 武夷学院 一种化合物的制备方法及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725385A (en) 1970-11-02 1973-04-03 Abbott Lab Process for the demethylation of 3-amino macrolides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
MY113693A (en) 1992-05-26 2002-05-31 Chugai Pharmaceutical Co Ltd Erythromycin derivatives having an enterokinesis stimulating action
US6927057B2 (en) 1993-09-20 2005-08-09 Kosan Biosciences Macrolide analogs
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
DK1025114T3 (da) * 1997-09-30 2004-07-05 Abbott Lab 3'-N-modificerede 6-O-substituerede erythromycin-ketolidderivater med antibakteriel aktivitet
US6124269A (en) 1997-10-29 2000-09-26 Abbott Laboratories 2-Halo-6-O-substituted ketolide derivatives
ZA989885B (en) 1997-10-31 1999-05-05 Abbott Lab Use of macrolides for the treatment of cancer and macular degeneration
WO1999063929A2 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
IT1301968B1 (it) 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
GB9821938D0 (en) 1998-10-09 1998-12-02 Zeneca Ltd Chemical compounds
HRP980646B1 (en) 1998-12-30 2008-02-29 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. Novel oleandomycin derivatives
US6514944B2 (en) 1999-04-16 2003-02-04 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
US6451768B1 (en) 1999-04-16 2002-09-17 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
EP1101769A3 (en) 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
JP2003522763A (ja) 2000-02-10 2003-07-29 ファルマシア・アンド・アップジョン・カンパニー ピペラジンアミド置換基を持つオキサゾリジノンチオアミド
CA2399198A1 (en) 2000-02-18 2001-08-23 Christopher Carreras Motilide compounds
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
ATE321770T1 (de) 2000-08-17 2006-04-15 Kitasato Inst Pseudoerythromycin-derivate
BR0113472A (pt) 2000-08-22 2003-07-01 Basilea Pharmaceutica Ag Macrolìdeos com atividade antibacteriana
AU2002225724A1 (en) 2000-12-01 2002-07-08 Kosan Biosciences, Inc. Motilide compounds
WO2003004509A2 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US7396847B2 (en) 2001-09-11 2008-07-08 Astrazeneca Ab Oxazolidinone and/or isoxazoline as antibacterial agents
EP1443930A1 (en) 2001-10-25 2004-08-11 AstraZeneca AB Isoxazoline derivatives useful as antimicrobials
JP2005538927A (ja) 2002-01-17 2005-12-22 コーザン バイオサイエンシス インコーポレイテッド アミドマクロライド
US8063021B2 (en) 2002-01-17 2011-11-22 Kosan Biosciences Incorporated Ketolide anti-infective compounds
US6992069B2 (en) 2002-04-30 2006-01-31 Yu-Gui Gu Tricyclic macrolide antibacterial compounds
US20050045585A1 (en) * 2002-05-07 2005-03-03 Gang Zhang Method of electrochemically fabricating multilayer structures having improved interlayer adhesion
AU2003240482B2 (en) * 2002-05-30 2009-03-12 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
ITMI20021726A1 (it) 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
AR043050A1 (es) * 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
CN1780846A (zh) 2003-03-05 2006-05-31 Rib－X医药品有限公司 双官能杂环化合物及其制备和使用方法
WO2004078771A1 (ja) 2003-03-07 2004-09-16 Taisho Pharmaceutical Co., Ltd. ２－フルオロ－６－ｏ－置換ケトライド誘導体
ES2552682T3 (es) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
US7163924B2 (en) 2003-04-25 2007-01-16 Chiron Corporation Ketolide derivatives
US7332476B2 (en) 2003-04-25 2008-02-19 Novartis Ag Pyridyl substituted ketolide antibiotics
JP5043428B2 (ja) * 2003-06-03 2012-10-10 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその製造および使用方法
WO2005042554A1 (en) 2003-10-30 2005-05-12 Rib-X Pharmaceuticals, Inc. Bifunctional macrolide heterocyclic compounds and methods of making and using the same
JP2007512256A (ja) 2003-11-18 2007-05-17 リブ−エックス ファーマシューティカルズ，インコーポレイテッド 二官能性マクロライド複素環化合物ならびにこれらを製造する方法およびこれらを使用する方法
WO2005067919A1 (en) 2003-12-24 2005-07-28 Enanta Pharmaceuticals, Inc. 11-csubsituted erythromycin derivatives
JP5383037B2 (ja) * 2004-02-27 2014-01-08 リブ−エックス ファーマシューティカルズ，インコーポレイテッド 大環状化合物およびそれらを製造し使用する方法
WO2005118610A2 (en) 2004-06-01 2005-12-15 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
US7402568B2 (en) 2004-09-29 2008-07-22 Enanta Pharmaceuticals, Inc. Bicyclic 9a-azalide derivatives
US7419962B2 (en) 2004-12-07 2008-09-02 Enanta Pharmaceuticals, Inc. 3,6-bicyclolides
US7229972B2 (en) 2004-12-07 2007-06-12 Enanta Pharmaceuticals, Inc. 3,6-Bicyclolides
US7312201B2 (en) 2004-12-13 2007-12-25 Enanta Pharmaceuticals, Inc. Tetracyclic bicyclolides
UA85937C2 (uk) 2004-12-21 2009-03-10 Пфайзер Продактс Інк. Макроліди
US7271155B2 (en) 2005-01-07 2007-09-18 Enanta Pharmaceuticals, Inc. 9A, 11-2C-bicyclic 9a-azalide derivatives
EP3290427A1 (en) * 2005-08-24 2018-03-07 Melinta Therapeutics, Inc. Triazole compounds and methods of making and using the same
JP2009506063A (ja) * 2005-08-24 2009-02-12 リブ−エックス ファーマシューティカルズ，インコーポレイテッド トリアゾール化合物ならびにこれを作製する方法および使用する方法

Also Published As

Publication number Publication date
JP5981401B2 (ja) 2016-08-31
US20100016956A1 (en) 2010-01-21
WO2007025098A2 (en) 2007-03-01
JP2019023194A (ja) 2019-02-14
WO2007025098A3 (en) 2007-04-26
US20130065845A1 (en) 2013-03-14
US20160031926A1 (en) 2016-02-04
US9006189B2 (en) 2015-04-14
EP1934238A1 (en) 2008-06-25
JP2009506075A (ja) 2009-02-12
EP3290427A1 (en) 2018-03-07
US20180094016A1 (en) 2018-04-05
US8278281B2 (en) 2012-10-02
ES2638427T3 (es) 2017-10-20
EP1928893A2 (en) 2008-06-11
WO2007025284A1 (en) 2007-03-01
DK1934238T3 (en) 2017-09-18
JP2016094421A (ja) 2016-05-26
EP1934238B1 (en) 2017-06-28
HRP20171285T1 (hr) 2017-10-20
JP2013256517A (ja) 2013-12-26
JP2018008970A (ja) 2018-01-18
US20140088031A1 (en) 2014-03-27
WO2007025284A8 (en) 2007-04-26
JP2009506066A (ja) 2009-02-12

Similar Documents

Publication Publication Date Title
JP5981401B2 (ja) トリアゾール化合物ならびにこれを作製する方法および使用する方法
JP5631909B2 (ja) 大環状化合物およびそれらを製造し使用する方法
WO2008106226A2 (en) Macrolide compounds and methods of making and using the same
US9085600B2 (en) Triazole compounds and methods of making and using the same
JP2006523229A (ja) 二官能性複素環式化合物ならびにその製造および使用方法
WO2018191682A1 (en) Triazole compounds and methods of making and using the same
CN108101948A (zh) 大环化合物以及其制作和使用方法
HK1178906A (en) Macrocyclic compounds and methods of making and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130510

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131018

R150 Certificate of patent or registration of utility model

Ref document number: 5395432

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees